Profile data is unavailable for this security.
About the company
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. It is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-31.60m
- Incorporated2007
- Employees9.00
- LocationMinerva Neurosciences Inc1601 TRAPELO ROAD, SUITE 284WALTHAM 02451United StatesUSA
- Phone+1 (617) 600-7373
- Fax+1 (302) 636-5454
- Websitehttps://www.minervaneurosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KALA BIO Inc | 0.00 | -39.55m | 19.07m | 43.00 | -- | 2.86 | -- | -- | -15.15 | -15.15 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -63.15 | -57.83 | -76.71 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -12.26 | 0.8382 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| Synlogic Inc | 3.21m | -73.22m | 19.32m | 6.00 | -- | 1.44 | -- | 6.03 | -10.62 | -10.62 | 0.4576 | 1.15 | 0.0495 | -- | -- | 534,166.70 | -113.09 | -40.57 | -134.57 | -43.82 | -- | -- | -2,284.68 | -3,245.93 | -- | -- | 0.00008 | -- | 185.68 | 5.99 | 13.40 | -- | -48.05 | -- |
| MEI Pharma Inc | 66.75m | 26.16m | 19.39m | 46.00 | 0.7413 | 0.38 | 0.7314 | 0.2905 | 3.93 | 3.93 | 10.02 | 7.66 | 0.6498 | -- | 29.15 | 1,451,174.00 | 25.46 | -25.31 | 30.38 | -28.59 | -- | -- | 39.18 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -16.58m | 19.53m | 8.00 | -- | 1.94 | -- | -- | -3.26 | -3.26 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -68.36 | -95.57 | -108.01 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Lyra Therapeutics Inc | 1.68m | -68.88m | 19.81m | 109.00 | -- | 0.2556 | -- | 11.79 | -1.23 | -1.23 | 0.0297 | 1.27 | 0.0143 | -- | -- | 19,090.91 | -58.52 | -58.01 | -68.02 | -68.69 | -- | -- | -4,099.82 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Microbot Medical Inc | 0.00 | -10.26m | 19.87m | 22.00 | -- | 3.22 | -- | -- | -0.8926 | -0.8926 | 0.00 | 0.4283 | 0.00 | -- | -- | 0.00 | -151.13 | -53.28 | -183.85 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
| Polypid Ltd | 0.00 | -24.25m | 19.91m | 59.00 | -- | 2.79 | -- | -- | -12.35 | -12.35 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -84.94 | -76.92 | -120.03 | -89.61 | -- | -- | -- | -- | -- | -28.72 | 0.5498 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
| Correlate Energy Corp | 7.95m | -13.85m | 20.06m | 19.00 | -- | -- | -- | 2.52 | -0.3747 | -0.3747 | 0.2157 | -0.145 | 2.76 | -- | 26.10 | 418,160.50 | -481.76 | -315.47 | -- | -- | 17.98 | 15.42 | -174.38 | -201.03 | -- | -1.07 | -- | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
| Minerva Neurosciences Inc | 0.00 | -31.60m | 20.21m | 9.00 | -- | -- | -- | -- | -4.48 | -4.48 | 0.00 | -5.23 | 0.00 | -- | -- | 0.00 | -61.90 | -49.89 | -65.32 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
| Neurosense Therapeutics Ltd | 0.00 | -11.28m | 20.38m | 16.00 | -- | -- | -- | -- | -0.7625 | -0.7625 | 0.00 | -0.1219 | 0.00 | -- | -- | 0.00 | -207.24 | -- | -395.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.59 | -- | -- | -- |
| Jaguar Health Inc | 10.14m | -38.32m | 20.49m | 49.00 | -- | 1.59 | -- | 2.02 | -78.63 | -78.63 | 9.90 | 3.18 | 0.1806 | 0.2397 | 8.12 | 206,938.80 | -69.22 | -95.29 | -122.86 | -163.54 | 79.07 | 67.28 | -383.35 | -522.28 | 1.39 | -2.78 | 0.6919 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| Sol Gel Technologies Ltd | 1.72m | -22.86m | 20.63m | 36.00 | -- | 0.6317 | -- | 11.99 | -0.8222 | -0.8222 | 0.0619 | 1.17 | 0.0387 | -- | 0.5154 | 47,777.78 | -51.40 | -31.60 | -57.29 | -35.49 | -- | -- | -1,329.13 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
| Ibio Inc | 50.00k | -17.13m | 20.78m | 26.00 | -- | 0.8256 | -- | 415.66 | -13.10 | -17.09 | 0.0262 | 2.92 | 0.0011 | -- | 0.0065 | 1,923.08 | -36.24 | -28.09 | -67.39 | -32.63 | -- | -- | -34,258.00 | -1,467.30 | -- | -- | 0.3666 | -- | -100.00 | -- | 0.9764 | -- | 42.90 | -- |
| Bioxytran Inc | 0.00 | -4.30m | 21.00m | 2.00 | -- | -- | -- | -- | -0.0297 | -0.0297 | 0.00 | -0.0017 | 0.00 | -- | -- | -- | -2,431.80 | -1,420.53 | -- | -- | -- | -- | -- | -- | -- | -7.69 | -- | -- | -- | -- | -73.71 | -- | -- | -- |
| Cumberland Pharmaceuticals, Inc. | 38.83m | -8.42m | 21.00m | 91.00 | -- | 0.7624 | -- | 0.541 | -0.596 | -0.596 | 2.72 | 1.94 | 0.4542 | 0.8812 | 3.08 | 426,654.70 | -9.83 | -7.03 | -14.07 | -9.52 | 83.54 | 79.95 | -21.65 | -17.64 | 1.21 | -37.10 | 0.3717 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Forte Biosciences Inc | 0.00 | -32.14m | 21.17m | 11.00 | -- | 0.7372 | -- | -- | -1.03 | -1.03 | 0.00 | 0.7882 | 0.00 | -- | -- | 0.00 | -93.54 | -72.06 | -104.30 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
Data as of Jun 07 2024. Currency figures normalised to Minerva Neurosciences Inc's reporting currency: US Dollar USD
29.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Federated Global Investment Management Corp.as of 31 Mar 2024 | 1.35m | 19.32% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 250.06k | 3.58% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 177.77k | 2.54% |
| UBS O'Connor LLCas of 31 Mar 2024 | 99.64k | 1.43% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 72.67k | 1.04% |
| Geode Capital Management LLCas of 31 Mar 2024 | 52.59k | 0.75% |
| BG Fund Management Luxembourg SAas of 31 Dec 2023 | 20.58k | 0.29% |
| NFS Netfonds Financial Service GmbHas of 30 Sep 2023 | 17.50k | 0.25% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 17.42k | 0.25% |
| G1 Execution Services LLCas of 31 Mar 2024 | 16.68k | 0.24% |
More ▼
Data from 28 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
